

Restalyst

## Short profile

Name: Restalyst

Medical field	Cancer
Product type	Medical Devices, Diagnostics, and Therapeutics
Growth stage	Other
Team	<10 people

### Description of product:

Restalyst has successfully developed and launched three cancer tests for early detection of cancer for nose, stomach and liver cancer.

- GC-REAAD™ ITIH3 ELISA is intended for qualitative and semi-quantitative detection of human Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) proteins which aid in the diagnosis of gastric cancer.
- HCC-REAAD™ ERBB3 ELISA is intended for qualitative and semi-quantitative detection of human epidermal growth factor receptor 3 (ERBB3) proteins, aiding in the diagnosis of Hepatocellular Carcinoma.

### Desired project goal: *Please also elaborate on the primary outcome*

The company is proposing the following project scopes:

- Clinical evaluation of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA using retrospective cohort of samples
- Performance evaluation under IVDR of GC-REAAD™ ITIH3 and HCC-REAAD™ ERBB3 ELISA

### Desired project type: *Please also elaborate on the following points, if applicable: population, intervention, study design etc.*

Co-innovation, clinical and performance evaluation



Ivan.lim@restalyst.com



+65 6229 6025



www.restalyst.com